ACTU
USDActuate Therapeutics Inc. Common stock
即時價格
價格圖表
關鍵指標
市場指標
開盤
$6.500
最高
$6.660
最低
$6.461
交易量
0.02M
公司基本面
市值
153.2M
行業
生物科技
國家
United States
交易統計
平均交易量
0.07M
交易所
NGM
貨幣
USD
52週範圍
相關新聞
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics with a Buy and maintains $20 price target.
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapiesRecent financing provides extended runway through
Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option
CHICAGO and FORT WORTH, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for
Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock
CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for
Actuate Therapeutics Announces Proposed Public Offering of Common Stock
CHICAGO and FORT WORTH, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for
